SARS-CoV-2 Coronavirus COVID Vaccine Market Analysis & Forecast Report to 2026

SARS-CoV-2 Coronavirus COVID Vaccine Market Analysis & Forecast Report to 2026

4,24112,723

COVID Vaccine Market Report Includes:

  • Financial market forecast through 2026 with CAGR values of all market segments – vaccine technology, geography (US, EU, UK, Japan, RoW) & major players
  • Global COVID vaccine market analysis, vaccine technology breakdown & leading market players – Pfizer, BioNTech, Moderna, AstraZeneca, J&J, NovaVax, Sinovac, Gamaleya
  • Advance purchase agreements, marketed products, financial analysis & business strategy
  • Focus on current trends, business environment, pipeline products, clinical trials
  • Insight into challenges faced by stakeholders, particularly manufacturers & governments
  • Influence of the molecular diagnostics, PCR testing & POC testing landscapes
  • Insight into the emergence of variants & impact on vaccine effectiveness & the overall market

For more information or complimentary sample pages please email deirdre@kellysci.com

Clear

Description

SARS-CoV-2 Coronavirus COVID Vaccine Market Analysis Report & Forecast to 2026

The SARS-CoV-2 Coronavirus COVID vaccine market analysis report provides a comprehensive overview of the size of the SARS-CoV-2 COVID Vaccine market, segmentation of the industry (by geography and vaccine technology), key players and the vast potential of vaccines that are in clinical trials. The key players dominating the COVID vaccine market at present include Pfizer, BioNTech, Moderna, AstraZeneca and J&J. Our analysis indicates that the global COVID vaccine market was worth over $59 billion in 2021. However, our senior analysts forecast that an initial drop will occur in 2022 due to a number of factors including single booster shots as opposed to two shot vaccines and reduced prices in vaccines due to competition.

How Will the COVID Vaccine Market Grow in an Endemic Phase to 2026?

The COVID vaccine industry is expected to then grow significantly at a CAGR of over 9% and reach $47.5 billion by 2026. This is due to an opening up of the market from a closed government-dominated space to one in which private healthcare providers and companies can purchase vaccines. There will also be a continued significant un-met need for vaccine boosters in an endemic situation.

Challenges of Mutations and Threats of Future Variants to the Vaccine Market

The emergence of SARS-CoV-2 spike protein mutations globally have enabled the virus to become more infectious. Sequencing thousands of samples have enabled the identification of the most common mutations thus far including B.1.1.7 (UK), B.1.351 (South Africa) and P1 lineage (Japan/Brazil). Mutations such as these give the virus an evolutionary advantage for selection as they allow for protein structural changes in the spike protein. This is most notable in Ireland which had a 5% prevalence of the B.1.1.7 strain in December 2020, which increased dramatically to 90% prevalence by February 2021. The B.1.1.7 strain contains numerous mutations in the spike region which give it a higher affinity to attach to human cells. Studies to date estimate that this variant is between 30-50% more infectious than the original strain.

Will this Have an Effect on the Efficacy of Vaccines?

Mutations arising in the spike protein of variants pose a potential problem for the efficacy of vaccines. This is due to the fact that vaccines to date target the spike protein, and so neutralizing antibodies and the T cell response are primed against the original spike protein structure. With regards the South African B1.351 variant, serum from individuals who received the Moderna mRNA-1273 vaccine were shown to have lower neutralization ability in in vitro assays. However, even though neutralization ability was lower, it was still significant.

A similar study demonstrated that neutralization of a virus containing three mutations from the South African variant from sera from individuals vaccinated with Pfizer/BioNTech BNT162b2 was lower than the UK variant. However, the study indicated that differences in neutralization was very small. This study indicates that the Pfizer/BioNtech vaccine still works against the South African strain, but is slightly less effective. Similarly, the AstraZeneca, Novavax and J&J vaccines also show slightly less protection.

A recent report in the New England Journal of Medicine evaluated a study group of 596,618 vaccinated people (matched to unvaccinated controls) in Israel for BNT162b2 COVID vaccine effectiveness. Their results indicated that BNT162b2 vaccination is highly effective in a real world population, and mirrors clinical trial results thus far.

This report describes the evolution of such a huge market in 8 chapters supported by over 74 tables and figures in over 137 pages.

The report focuses on the following:

  • An overview of the SARS-CoV2 virus that includes: genetic and structural analysis, mutation and variant characterization
  • Global COVID vaccine market, global landscape analysis, vaccine technology breakdown and leading market players
  • Advance purchase agreements, marketed/pipeline products, financial analysis and business strategy of the major companies in this space
  • Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for COVID vaccines to 2026
  • Clinical trial timelines for major vaccines in the pipeline
  • Insight into the challenges faced by stakeholders, particularly manufacturers and governments
  • Insight into the emergence of variants and their impact on vaccine effectiveness and the overall market
  • Financial market forecast through 2026 with CAGR values of all market segments – vaccine technology, geography (US, EU, UK, Japan, RoW) and major players
  • Influence of the molecular diagnostics, PCR testing and POC testing landscapes
  • Numbers of vaccine doses available by each manufacturer per annum
  • Geographical analysis and challenges within countries with respect to advance purchase agreements and distribution channels

 

For more information or complimentary sample pages please email deirdre@kellysci.com

 

Additional information

Licence Types

Enterprise Wide Licence, Mid Level Licence (up to 10 people), Single User Licence